ABL Bio KRX:298380KOSDAQ
에이비엘바이오 · Korean news coverage and regulatory filings, organized.
Articles, 24h3
Articles, 7 days4
DART filings, 7 days0
Articles tracked4since Sep 11
In Q2 2026, ABL Bio reported revenue of ₩19.7bn, down 74.0% year on year, and an operating loss of ₩16.8bn. ABL Bio (에이비엘바이오) appeared in 4 Korean news articles and 0 DART filings over the past seven days. Coverage peaked on Sep 15 with 3 articles. The most common catalyst was risk & warnings (1). It was most often mentioned alongside Alteogen.
ABL Bio quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩19.7bn | -74.0% | −₩16.8bn | −₩15.0bn |
| Q1 2026 | ₩13.1bn | +506.8% | −₩17.2bn | −₩14.7bn |
| Q4 2025 derived | ₩0m | -100.0% | −₩29.7bn | −₩28.2bn |
| Q3 2025 | ₩1.4bn | -81.8% | −₩22.4bn | −₩21.3bn |
| Q2 2025 | ₩75.7bn | +797.2% | ₩40.7bn | ₩39.8bn |
| Q1 2025 | ₩2.2bn | -72.7% | −₩29.0bn | −₩28.1bn |
| Q4 2024 derived | ₩9.1bn | +13.5% | −₩19.1bn | −₩19.0bn |
| Q3 2024 | ₩7.9bn | -7.4% | −₩14.7bn | −₩13.1bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases.
ABL Bio top stories 2 weeks, by number of outlets
- 1
- 2
- 3
- 4
